ABSTRACT
Currently, prostate cancer is the number one cause of mortality in men in Mexico, and number two globally (Meneses-Garcia et al. 2012; Li et al. 2016). Thus, there is an imperative to attend to the causes and treatment of this disease. Although there are therapies that inhibit progression of the disease, they fail to eradicate it. Relapse after controlling the progression can occur, accompanied by more aggressive cell growth that is often fatal. Because the prostate is an accessory sex gland, the development and maintenance of which depends on androgen, therapies designed to prevent the progression of prostate disease are directed at inhibiting the action of testosterone or its metabolite, dihydrotestosterone (DHT) (Hoque et al. 2015). Prolactin (PRL) also plays a role in the regulation of the prostate, and in some reports, PRL blood levels
15.1 Introduction ................................................................................................ 263 15.2 Overview .....................................................................................................264
